IRCT20110628006907N18尚未招募2 期
A Triple blinded, Parallel Randomized clinical trial Phase II&III of 3 Times Intrathecal Injections of an Umbilical Cord-Derived Mesenchymal Stromal Cell Product WhartoCell” in Children with Cerebral Palsy
ROYAN stem cell technology Co0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 years 至 14 years（—）
- 性别
- All
入选标准
- •Spastic cerebral palsy (Dip, Quadri, Hemiparetic ) Ages between 2 - 14 years Gross motor function classification (GMFC) 2 -4 No seizure disorder or with controlled seizure Acquired brain MRI finding compatible with CP Informed consent of parents
排除标准
- •Normal brain MRI Progressive neurological diseases Congenital brain cortical malformations TORCH infections( Toxoplasmosis, Others, Rubella Cytomegalovirus Hepatitis C ) Other types of cerebral palsy (athetoid , atonic , ataxic , mixed ) Acute infections (Human Immunodeficiency Virus , Hepatitis C Virus ) Hemorrhagic diathesis Severe anemia ( Hemoglobin less than 8 ) Ventilator dependent pulmonary diseases Severe renal dysfunction Severe liver dysfunction
研究者
相似试验
进行中（未招募）
1 期
eoadjuvant chemotherapy with Atezolizumab or Placebo followed by adjuvant Atezolizumab or PlaceboPatients with early breast cancerMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002771-25-DESABP Foundation Inc.1,550
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo GeparDouzePatients with early breast cancerMedDRA version: 20.0Level: LLTClassification code: 10007050Term: Cancer Class: 10029104CTIS2023-508472-11-00SABP Foundation Inc.1,550
进行中（未招募）
1 期
eoadjuvant chemotherapy with Atezolizumab or Placebo followed by adjuvant Atezolizumab or PlaceboPatients with early breast cancerMedDRA version: 20.0 Level: LLT Classification code 10007050 Term: Cancer System Organ Class: 100000004864EUCTR2017-002771-25-ESSABP Foundation Inc.1,520
尚未招募
3 期
CV638 ability to protect against homologous Vibrio cholerae 3008 virulent straicholera infectionVibrio InfectionsGram-Negative Bacterial InfectionsBacterial InfectionsWaterborne DiseasesEnvironmental IllnessCholeraRPCEC00000228Finlay Institute of Vaccines (IFV)120
进行中（未招募）
1 期
A study to confirm efficacy and safety of dasiglucagon to rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo and with reference to GlucaGen®Type 1 diabetes mellitusMedDRA version: 20.0 Level: SOC Classification code 10027433 Term: Metabolism and nutrition disorders System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-002449-31-DEZealand Pharma A/S170